Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Progyny Inc (PGNY) USD0.0001

Sell:$42.77 Buy:$42.78 Change: $1.18 (2.68%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
Sell:$42.77
Buy:$42.78
Change: $1.18 (2.68%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
Sell:$42.77
Buy:$42.78
Change: $1.18 (2.68%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Progyny, Inc. is a fertility benefits management company specializing in fertility and family building benefits solutions in the United States. The Company operates in one segment that is providing fertility and pharmacy benefits solutions. The Company also offers a benefits plan for the doctors and members. In addition to its fertility benefits solution, it offers an integrated pharmacy benefits solution, Progyny Rx. Progyny Rx provides its members with access to the medications needed during their fertility treatments.

Contact details

Address:
1359 BROADWAY, 2ND FLOOR
NEW YORK
10018
United States
Telephone:
+1 (212) 8883124
Website:
https://www.progyny.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PGNY
ISIN:
US74340E1038
Market cap:
$3.73 billion
Shares in issue:
87.22 million
Sector:
Managed Health Care
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Beth Seidenberg
    Independent Chairman of the Board of Directors
  • Peter Anevski
    President, Chief Operating Officer
  • David Schlanger
    Chief Executive Officer, Director
  • Mark Livingston
    Chief Financial Officer, Principal Accounting Officer
  • Jennifer Bealer
    Executive Vice President, General Counsel
  • Lisa Greenbaum
    Executive Vice President, Chief Client Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.